代谢相关脂肪性肝病进展与多系统共病的关联机制及整合管理策略

王丽苹; 李娅; 任岳波; 何婷婷; 王仲霞; 闫丽萍; 余思邈; 景婧; 孙永强; 张傲哲; 王鑫; 肖小河; 陆荫英; 王睿林

doi:10.12449/JCH260828

代谢相关脂肪性肝病进展与多系统共病的关联机制及整合管理策略

DOI: 10.12449/JCH260828

1.
中国人民解放军总医院肝病医学部中西医结合肝胆病科，北京 100039
2.
中国人民解放军总医院第五医学中心营养科，北京 100039
3.
中国人民解放军总医院肝病医学部门脉高压科，北京 100039
4.
中国人民解放军总医院肝病医学部肝病研究所，北京 100039
5.
中国人民解放军总医院肝病医学部，北京 100039

基金项目:

国家自然科学基金青年科学基金 (82505719)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：王睿林、肖小河、陆荫英负责整体思路和论文框架设计，指导、撰写、修改文章并最后定稿；李娅、任岳波、何婷婷、王仲霞、闫丽萍、余思邈、景婧、孙永强、张傲哲和王鑫负责文献查阅；王丽苹负责研究设计，初稿撰写及全文修订。

详细信息

通信作者:
王睿林， wrl7905@163.com （ORCID： 0000-0002-7129-016X）

计量
- 文章访问数: 13
- HTML全文浏览量: 3
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2025-11-26
- 录用日期: 2026-03-26
- 出版日期: 2026-08-25

Association mechanisms between the progression of metabolic dysfunction-associated fatty liver disease and multi-system comorbidities and integrated management strategies

1.
Department of Integrated Traditional Chinese and Western Medicine Hepatobiliary Diseases，Senior Department of Liver Disease，Chinese PLA General Hospital，Beijing 100039，China
2.
Department of Nutrition，The Fifth Medical Center of Chinese PLA General Hospital，Beijing 100039，China
3.
Department of Portal Hypertension，Senior Department of Hepatology，Chinese PLA General Hospital，Beijing 100039，China
4.
Institute of Hepatology，Senior Department of Liver Disease，Chinese PLA General Hospital，Beijing 100039，China
5.
Senior Department of Liver Disease，Chinese PLA General Hospital，Beijing 100039，China

Research funding:

National Natural Science Foundation of China Youth Science Fund Project (82505719)

More Information

Corresponding author: Wang Ruilin， wrl7905@163.com （ORCID： 0000-0002-7129-016X）

摘要

摘要: 代谢相关脂肪性肝病（MAFLD）已成为全球最常见的慢性肝病，其病理进程以“二次打击”学说为核心，肠-肝轴紊乱贯穿从脂肪变性至肝硬化乃至肝细胞癌的全病程，并通过“肠-肝-脑轴”“肝-肾轴”“肝-心轴”等多维通路，与代谢、心血管、肾脏及精神神经系统形成广泛的跨系统交互调控机制。疾病进展不仅局限于肝脏本身，更涉及全身多器官系统的功能失衡。本文系统阐述MAFLD“肝脏病理进展-多轴调控-共病发生”的关联机制，提出基于风险分层的早期筛查、靶向干预与多学科诊疗协同管理策略，并分析当前研究的局限与未来发展方向，以期为MAFLD的精准诊疗与个性化管理提供理论依据与实践指导。
- 代谢相关脂肪性肝病 /
- 肝纤维化 /
- 肠-肝轴 /
- 慢性病共病
Abstract: Metabolic dysfunction-associated fatty liver disease （MAFLD） has become the most common chronic liver disease worldwide. Its pathological process is centered on the “two-hit” theory， with gut-liver axis dysregulation running through the entire disease course from steatosis to liver cirrhosis and even hepatocellular carcinoma， and it forms an extensive cross-system regulatory mechanism with the metabolic， cardiovascular， renal， and psychological and nervous systems through multi-dimensional pathways such as the “gut-liver-brain axis”， the “liver-kidney axis”， and the “liver-heart axis”. Disease progression is not limited to the liver itself， and it also involves functional imbalance of multiple organ systems throughout the body. This article systematically elaborates on the association mechanism of “liver pathological progression-multi-axis regulation-comorbidity occurrence” in MAFLD， proposes synergistic management strategies integrating early screening based on risk stratification， targeted intervention， and multidisciplinary diagnosis and treatment， and analyzes the limitations of current research and future development directions， in order to provide a theoretical basis and practical guidance for precise diagnosis and treatment and individualized management of MAFLD.
- Metabolic Dysfunction-Associated Fatty Liver Disease /
- Hepatic Fibrosis /
- Gut-Liver Axis /
- Multiple Chronic Conditions

HTML全文

参考文献(26)

[1]	Huang Weishen. The prevalence of metabolic dysfunction-associated fatty liver disease in Asia[J]. J Clin Hepatol, 2025, 41( 9): 1721- 1724. DOI: 10.12449/JCH250901. 黄炜燊. 亚洲地区代谢相关脂肪性肝病流行情况[J]. 临床肝胆病杂志, 2025, 41( 9): 1721- 1724. DOI: 10.12449/JCH250901.
[2]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of metabolic dysfunction-associated(non-alcoholic) fatty liver disease(version 2024)[J]. J Pract Hepatol, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163. 中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163.
[3]	Zhang Ruonan, He Junhua. Research progress on the mechanism of non-alcoholic fatty liver disease caused by hepatic insulin resistance[J]. Chin J Clin Res, 2024, 37( 7): 998- 1002. DOI: 10.13429/j.cnki.cjcr.2024.07.003. 张若男, 何军华. 肝脏胰岛素抵抗引起非酒精性脂肪性肝病相关机制研究进展[J]. 中国临床研究, 2024, 37( 7): 998- 1002. DOI: 10.13429/j.cnki.cjcr.2024.07.003.
[4]	Zhang Yang, Li Junxiang, Wang Yunliang. Role of bile acid metabolism and related receptors in the development and progression of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36( 6): 1374- 1377. DOI: 10.3969/j.issn.1001-5256.2020.06.040. 张阳, 李军祥, 王允亮. 胆汁酸代谢及其受体在非酒精性脂肪性肝病发生发展中的作用[J]. 临床肝胆病杂志, 2020, 36( 6): 1374- 1377. DOI: 10.3969/j.issn.1001-5256.2020.06.040.
[5]	Tan Ming, Zhang Hui, Ren Jihua, et al. The role of lipid metabolism disorders in non-alcoholic fatty liver disease[J]. Chin J Gastroenterol Hepatol, 2024, 33( 8): 1082- 1086. DOI: 10.3969/j.issn.1006-5709.2024.08.025. 谭明, 张慧, 任吉华, 等. 脂质代谢紊乱在非酒精性脂肪性肝病中的作用概述[J]. 胃肠病学和肝病学杂志, 2024, 33( 8): 1082- 1086. DOI: 10.3969/j.issn.1006-5709.2024.08.025.
[6]	Chen Ruiying, Lin Yining. Biological mechanism of liver lipid metabolism in the occurrence and development of nonalcoholic fatty liver disease[J]. Jiangxi Med J, 2021, 56( 3): 399- 401. DOI: 10.3969/j.issn.1006-2238.2021.03.041. 陈芮莹, 林以宁. 肝脏脂质代谢在非酒精性脂肪性肝病发生发展中的生物学机制[J]. 江西医药, 2021, 56( 3): 399- 401. DOI: 10.3969/j.issn.1006-2238.2021.03.041.
[7]	Yang Bingqing, Yin Jingya, Wang Qi. The mechanism of action of mitochondrial dysfunction in the development of non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2024, 40( 1): 147- 150. DOI: 10.12449/JCH240124. 杨冰清, 尹静亚, 王琦. 肝线粒体功能障碍在非酒精性脂肪性肝病发病中的作用机制[J]. 临床肝胆病杂志, 2024, 40( 1): 147- 150. DOI: 10.12449/JCH240124.
[8]	Gao Xiaoqin, Zhou Dan, Wang Shan, et al. Role of microbiota-gut-liver-brain axis on liver cirrhosis-associated neuropsychiatric diseases[J/CD]. Chin J Liver Dis Electron Version, 2025, 17( 3): 28- 33. DOI: 10.3969/j.issn.1674-7380.2025.03.004. 高晓琴, 周丹, 王珊, 等. 肠道微生物群-肠-肝-脑轴在肝硬化相关神经精神疾病中的作用[J/CD]. 中国肝脏病杂志(电子版), 2025, 17( 3): 28- 33. DOI: 10.3969/j.issn.1674-7380.2025.03.004.
[9]	Cai Yongxiang, Huang Huihui, Du Huan, et al. Research advances in the relationship between nonalcoholic fatty liver disease and cardiovascularrelated metabolic diseases[J]. Chin Circ J, 2024, 39( 12): 1244- 1248. DOI: 10.3969/j.issn.1000-3614.2024.12.015. 蔡永祥, 黄会慧, 都欢, 等. 非酒精性脂肪性肝病与心血管代谢疾病关系的研究进展[J]. 中国循环杂志, 2024, 39( 12): 1244- 1248. DOI: 10.3969/j.issn.1000-3614.2024.12.015.
[10]	Gao Jingyang. Effect of hepatic stellate cell FOXO1 on non-alcoholic steatohepatitis and liver fibrosis[D]. Shanghai: Tongji University, 2022. 高晶扬. 肝脏星状细胞FOXO1对非酒精性脂肪性肝炎及肝纤维化的影响[D]. 上海: 同济大学, 2022.
[11]	Zhang Hui, Tan Ming, Cheng Shengtao, et al. Mechanism of amino acid metabolism in nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2024, 40( 4): 810- 815. DOI: 10.12449/JCH240427. 张慧, 谭明, 程胜桃, 等. 氨基酸代谢在非酒精性脂肪性肝病中的作用机制[J]. 临床肝胆病杂志, 2024, 40( 4): 810- 815. DOI: 10.12449/JCH240427.
[12]	Gao Chanchan, Zhang Haibo, Wei Hailiang, et al. Dicussion on the effects of Yimu Naoye enema on TLR4-NF-κB-NLRP3 pathway in hepatic encephalopathy rats based on the enteric-hepato-brain axis[J]. China J Tradit Chin Med Pharm, 2023, 38( 6): 2599- 2604. 高婵婵, 张海博, 魏海梁, 等. 基于肠-肝-脑轴探讨益木脑液灌肠对肝性脑病大鼠TLR4/NF-κB/NLRP3通路的影响[J]. 中华中医药杂志, 2023, 38( 6): 2599- 2604.
[13]	Tan Qinwen, Du Yuanqin, Huang Hongna, et al. Mechanism of intestinal microecology/bile acid metabolism/FXR pathway in the development of NAFLD[J]. Chin J Integr Tradit West Med Liver Dis, 2023, 33( 5): 467- 470. DOI: 10.3969/j.issn.1005-0264.2023.005.023. 谭钦文, 杜沅沁, 黄鸿娜, 等. 肠道微生态/胆汁酸代谢/FXR途径在NAFLD发展进程中的作用机制[J]. 中西医结合肝病杂志, 2023, 33( 5): 467- 470. DOI: 10.3969/j.issn.1005-0264.2023.005.023.
[14]	Dong Lining, Isaak A, Praktiknjo M, et al. Myocardial fibrosis and inflammation in liver cirrhosis: MRI study of the liver-heart axis[J]. Int J Med Radiol, 2020, 43( 6): 737- 738. DOI: 10.19300/j.2020.r1001. 董力宁, Isaak A, Praktiknjo M, 等. 肝硬化病人的心肌纤维化与炎症: 肝-心轴MRI研究[J]. 国际医学放射学杂志, 2020, 43( 6): 737- 738. DOI: 10.19300/j.2020.r1001.
[15]	Wang Xiaofei, Huang Shutian. Nonalcoholic fatty liver disease and cardiovascular disease[J]. Int J Cardiovasc Dis, 2024, 51( 3): 167- 170. DOI: 10.3969/j.issn.1673-6583.2024.03.011. 王晓菲, 黄淑田. 非酒精性脂肪性肝病与心血管疾病[J]. 国际心血管病杂志, 2024, 51( 3): 167- 170. DOI: 10.3969/j.issn.1673-6583.2024.03.011.
[16]	Zhao Yafang, Yang Jinhui, Zheng Mengyao, et al. Research progress on the correlation between metabolic-associated fatty liver disease and type 2 diabetes mellitus[J]. Chin J Gastroenterol Hepatol, 2024, 33( 8): 1092- 1098. DOI: 10.3969/j.issn.1006-5709.2024.08.027. 赵娅芳, 杨晋辉, 郑梦瑶, 等. 代谢相关脂肪性肝病与2型糖尿病的相关性研究进展[J]. 胃肠病学和肝病学杂志, 2024, 33( 8): 1092- 1098. DOI: 10.3969/j.issn.1006-5709.2024.08.027.
[17]	Xue Shiyuan, Liu Chang, Jiang Yubo, et al. Research progress on pathogenesis and treatment of type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease[J]. Chin J Gerontol, 2025, 45( 3): 756- 762. DOI: 10.3969/j.issn.1005-9202.2025.03.057. 薛世圆, 刘畅, 江玉波, 等. 2型糖尿病合并非酒精性脂肪性肝病的发病机制及治疗的研究进展[J]. 中国老年学杂志, 2025, 45( 3): 756- 762. DOI: 10.3969/j.issn.1005-9202.2025.03.057.
[18]	Wu Wanwen, Li Xiaowei, Cui Lihong. The value of changes in diagnostic criteria for fatty liver in stratified management of cardiovascular risk[J]. Med J Chin People’s Liberation Army, 2021, 46( 5): 486- 491. DOI: 10.11855/j.issn.0577-7402.2021.05.10. 吴婉雯, 李晓伟, 崔立红. 脂肪肝诊断标准的变更对心血管疾病风险分层管理的价值分析[J]. 解放军医学杂志, 2021, 46( 5): 486- 491. DOI: 10.11855/j.issn.0577-7402.2021.05.10.
[19]	Jiang Tingting, Sun Fangfang, Zeng Zhan, et al. Progress on metabolic associated fatty liver disease related liver cancer[J/CD]. Chin J Liver Dis Electron Version, 2022, 14( 3): 14- 17. DOI: 10.3969/j.issn.1674-7380.2022.03.004. 蒋婷婷, 孙芳芳, 曾湛, 等. 代谢相关脂肪性肝病相关肝癌研究进展[J/CD]. 中国肝脏病杂志(电子版), 2022, 14( 3): 14- 17. DOI: 10.3969/j.issn.1674-7380.2022.03.004.
[20]	Zhang Yixiao, Sun Jianguang, Jiang Bowen. Research advances in the association of adipokines with metabolic associated fatty liver disease and its associated liver cancer[J]. J Clin Hepatol, 2025, 41( 1): 151- 158. DOI: 10.12449/JCH250123. 张熠潇, 孙建光, 蒋博文. 脂肪因子与代谢相关脂肪性肝病及其相关肝癌的关系[J]. 临床肝胆病杂志, 2025, 41( 1): 151- 158. DOI: 10.12449/JCH250123.
[21]	Wang Mingliang, Ding Yongfang, Yin Xin, et al. Progress in understanding hepatic fibrosis and renal fibrosis based on the gut-liver-kidney axis[J]. Acta Pharm Sin, 2021, 56( 1): 9- 20. DOI: 10.16438/j.0513-4870.2020-0710. 王明亮, 丁永芳, 印鑫, 等. 基于肠-肝-肾轴的肝纤维化与肾纤维化研究进展[J]. 药学学报, 2021, 56( 1): 9- 20. DOI: 10.16438/j.0513-4870.2020-0710.
[22]	Zhao Zhihui, Zhang Jianing, Liu Yijun, et al. Based on the“liver-kidney axis” and traditional Chinese medicine components, this paper discusses the mechanism of“treating different diseases at the same time” between diabetes and hyperlipidemia[J]. J Chin Med Mater, 2025, 48( 5): 1329- 1336. DOI: 10.13863/j.issn1001-4454.2025.05.042. 赵智慧, 张佳宁, 刘怡君, 等. 基于“肝-肾轴”与中药成分探讨糖尿病与高脂血症“异病同治”的作用机制[J]. 中药材, 2025, 48( 5): 1329- 1336. DOI: 10.13863/j.issn1001-4454.2025.05.042.
[23]	Wang Qin, Wei Lai. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease in children and adults in China and foreign countries: Comparison and analysis[J]. J Clin Hepatol, 2017, 33( 12): 2265- 2269. DOI: 10.3969/j.issn.1001-5256.2017.12.001. 王琴, 魏来. 国内外儿童与成人非酒精性脂肪性肝病诊疗指南的比较与解析[J]. 临床肝胆病杂志, 2017, 33( 12): 2265- 2269. DOI: 10.3969/j.issn.1001-5256.2017.12.001.
[24]	Xu Zhangrong. Interpretation of 2024 Edition of Multidisciplinary Clinical Practice Guidelines for Diabetes, Cardiorenal Diseases and Metabolic Diseases(V): Diabetes patients should pay attention to screening and prevention of metabolic fatty liver disease[J]. Chin J Diabetes Educ, 2025( 5): 30- 31. 许樟荣. 解读2024版《糖尿病、心肾及代谢性疾病的多学科临床实践指南》(五): 糖尿病患者要重视代谢性脂肪性肝病的筛查与预防[J]. 糖尿病之友, 2025( 5): 30- 31.
[25]	Zhou Meng, Bo Tao, Fan Xiude, et al. Metabolic dysfunction-associated fatty liver disease: A central hub in systemic metabolic dysregulation[J]. J Clin Hepatol, 2025, 41( 9): 1725- 1728. DOI: 10.12449/JCH250902. 周蒙, 薄涛, 范修德, 等. 代谢相关脂肪性肝病: 全身代谢性紊乱的核心枢纽之一[J]. 临床肝胆病杂志, 2025, 41( 9): 1725- 1728. DOI: 10.12449/JCH250902.
[26]	Jiang Lina, Zhao Jingmin. Pathological mechanism of multi-organ injuries in metabolic dysfunction-associated fatty liver disease[J]. J Clin Hepatol, 2025, 41( 9): 1729- 1736. DOI: 10.12449/JCH250903. 蒋丽娜, 赵景民. 代谢相关脂肪性肝病多器官损伤的病理机制[J]. 临床肝胆病杂志, 2025, 41( 9): 1729- 1736. DOI: 10.12449/JCH250903.